MedPath

Xalud Therapeutics, Inc.

Xalud Therapeutics, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2009-01-01
Employees
11
Market Cap
-
Website
http://www.xaludthera.com

Clinical Trials

8

Active:0
Completed:5

Trial Phases

2 Phases

Phase 1:6
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (75.0%)
Phase 2
2 (25.0%)

Safety Study of XT-150 in Participants With ALS

Phase 1
Not yet recruiting
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
First Posted Date
2024-11-26
Last Posted Date
2025-04-06
Lead Sponsor
Xalud Therapeutics, Inc.
Target Recruit Count
8
Registration Number
NCT06704347
Locations
🇺🇸

Barrow Neurological Institute (St. Joseph's), Phoenix, Arizona, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 1 locations

Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain

Phase 2
Completed
Conditions
Facet Joint Pain
Back Pain
Inflammation
Interventions
Biological: Placebo
First Posted Date
2022-01-19
Last Posted Date
2025-01-15
Lead Sponsor
Xalud Therapeutics, Inc.
Target Recruit Count
75
Registration Number
NCT05196919
Locations
🇺🇸

Neurovations, Napa, California, United States

🇺🇸

Source HealthCare, Santa Monica, California, United States

🇺🇸

Center for Clinical Research, Winston-Salem, North Carolina, United States

Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis

Phase 1
Withdrawn
Conditions
Osteoarthritis, Spine
First Posted Date
2021-04-12
Last Posted Date
2022-03-17
Lead Sponsor
Xalud Therapeutics, Inc.
Registration Number
NCT04841512
Locations
🇦🇺

Alfred Health, Melbourne, Victoria, Australia

Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain

Phase 1
Terminated
Conditions
Neuropathic Pain
First Posted Date
2020-07-10
Last Posted Date
2023-01-23
Lead Sponsor
Xalud Therapeutics, Inc.
Target Recruit Count
5
Registration Number
NCT04466410
Locations
🇦🇺

Genesis Research Services, Newcastle, New South Wales, Australia

🇦🇺

CerCare, Wayville, South Australia, Australia

🇦🇺

Metro Pain Group, Clayton, Victoria, Australia

and more 1 locations

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

Phase 2
Completed
Conditions
Osteoarthritis, Knee
Interventions
Drug: Placebo
First Posted Date
2019-10-11
Last Posted Date
2025-03-27
Lead Sponsor
Xalud Therapeutics, Inc.
Target Recruit Count
289
Registration Number
NCT04124042
Locations
🇺🇸

eStudySite, La Mesa, California, United States

🇺🇸

Neurovations (Napa Pain Institute), Napa, California, United States

🇺🇸

Source Healthcare, Santa Monica, California, United States

and more 3 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.